Johnson & Johnson Initiates IND Submission Of TAR-200 To Treat High-risk Bladder Cancer
(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...
birmingham.ac.uk9m
MRI scanning and biopsy could cut time to correct bladder cancer for by more than six weeks
BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster than those assessed with TURBT alone ...
J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer
The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...